

AMENDMENTS TO THE CLAIMS

Claims 1-11 (Cancelled).

12. (**Currently amended**) A process for treating a disease in a mammalian subject comprising administering to said subject an effective amount of a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject, wherein said intermediary metabolite is a glycolipid, and wherein said disease is cancer, a viral infection, or an autoimmune disease.

13. (Cancelled)

14. (Cancelled)

15. (Original) The process of claim 1214, wherein said glycolipid comprises a monosaccharide ceramide.

16. (Original) The process of claim 15, wherein said monosaccharide ceramide comprises a glucosyl ceramide or galatosyl ceramide.

17. (Original) The process of claim 12, wherein said administering step is carried out by means comprising intravenous means, intramuscular means, subcutaneous means, intra-peritoneal means or oral means.

18. (Cancelled)

19. (Cancelled)

20. (Original) The process of claim 1219, wherein said viral infection comprises HBV, HCV or HIV.

21. (Withdrawn; Currently amended) The process of claim 1218, wherein said autoimmune disease ~~immune dysfunction~~ comprises diabetes type I, diabetes type II, rheumatoid arthritis, Crohn's disease, arteriosclerosis and ulcerative colitis.

22. (Currently amended) The process of claim 12, wherein said reagent increases the rate of production of said glycolipid ~~mammalian intermediary metabolite~~ in said subject.

23. (Currently amended) The process of claim 12, wherein said reagent decreases the rate of degradation or turnover of said glycolipid ~~mammalian intermediary metabolite~~ in said subject.

24. (Original) The process of claim 12, wherein said mammalian subject comprises a human.

Claims 25-62 (Cancelled).

63. (New) The process of claim 15, wherein the viral infection is an HCV infection.

64. (New) The process of claim 16, wherein the viral infection is an HCV infection.